1616632-77-9
1616632-77-9
Chemical Structure
Dordaviprone
Synonym(s): TIC10; ONC-201
- No. CAS: 1616632-77-9
- Formula:C24H26N4O
- Molecular Weight:386.49
IUPAC Name: 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one
InChIKey: VLULRUCCHYVXOH-UHFFFAOYSA-N
SMILES: O=C1N(CC2=CC=CC=C2C)C3=NCCN3C4=C1CN(CC5=CC=CC=C5)CC4
Biological Activity: Dordaviprone (TIC10) is a potent, orally active, and stable tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) inducer which acts by inhibiting Akt and ERK, consequently activating Foxo3a and significantly inducing cell surface TRAIL. Dordaviprone can cross the blood-brain barrier[1].
| Referencia número | Nombre del producto | Pureza | Descripciòn | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Dordaviprone | 99.90% | Dordaviprone (TIC10) is a potent, orally active, and stable tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) inducer which acts by inhibiting Akt and ERK, consequently activating Foxo3a and significantly inducing cell surface TRAIL. Dordaviprone can cross the blood-brain barrier. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dexetimide hydrochloride | Dexetimide hydrochloride ((+)-Benzetimide hydrochloride) is an antimuscarinic drug with the activity of suppressing neuroleptic-induced Parkinson's syndrome. Dexetimide hydrochloride is used to improve the symptoms of movement disorders caused by the use of neuroleptics. Dexetimide hydrochloride, as the (-)-enantiomer of (-)-Benzetimide, shows the ability to selectively inhibit cholinergic receptors. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ONC212 | 99.86% | ONC212, a fluorinated-ONC201 analogue, is a promising anti-cancer agent and also a selective agonist of GPR132. ONC212 also induces apoptosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
NVP-DKY709 | 99.66% | NVP-DKY709 is an orally active and selective IKZF2 molecular glue degrader with the Dmax and DC50 of 53% and 4 nM, respectively. In addition, NVP-DKY709 can degrade IKZF4 (DC50: 13 nM) and SALL4 (DC50: 2 nM). NVP-DKY709 exerts anti-tumor activity by binding with CRBN to change conformation and recruit and degrade IKZF2. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
TIC10 isomer | 99.91% | TIC10 isomer is the isomer of TIC10. TIC10 isomer does not possess the reported biological activity of inducing TRIAL expression. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ONC213 | 99.86% | ONC213 is an orally active αKGDH inhibitor. ONC213 can suppress mitochondrial respiration and elevate α-ketoglutarate levels by inhibiting αKGDH activity. ONC213 can induce cells apoptosis by inducing mitochondrial stress response and inhibiting translation of MCL-1. ONC213 can be used for the research of cancer, such as acute myeloid leukemia research (AML). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ZYZ-17 | ZYZ-17 is an activator of human caseinolytic peptidase P ( hClpP), with an EC50 value of 0.24 μM. ZYZ-17 can be used in anticancer research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
HDAC6-IN-51 | HDAC6-IN-51 (Compound 7e) is a selective HDAC6 inhibitor with an IC50 value of 42.9 nM. HDAC6-IN-51 exhibits good anti-lung fibrosis activity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
TBP-134 | TBP-134 induce apoptosis primarily through DR5 and causes G2/M phase arrest. TBP-134 can be used in the research for pancreatic tumor. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AChE-IN-103 | AChE-IN-103 (Compound 10) is an inhibitor of ACh. AChE-IN-103 exhibits log IC50 values of 1.477 and 2.2 for models based on alignments I and II. AChE-IN-103 can be studied in research on Alzheimer’s disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ClpP agonist 1 | ClpP agonist 1 is a Staphylococcus aureus ClpP (SaClpP) agonist with an EC50 of 1.44 μM, Kd values of 2.95 μM (isothermal titration calorimetry) and 18 μM (bio-layer interferometry), and a low drug resistance frequency. ClpP agonist 1 reduces bacterial load, shrinks infected area and improves histopathological outcomes in a mouse skin infection model. ClpP agonist 1 can be used for the research of Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA) skin infections. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
